Tyligand Bioscience Ltd. HKEX Listing Application Lapses; Core Candidate Enters Phase 2 Clinical Trials
NewTimeSpace News: The listing application submitted by Tyligand Bioscience Ltd. to the Hong Kong Stock Exchange on 29 January 2026 has lapsed upon expiry of the six-month term. CICC served as the original sole sponsor.
Founded in 2017, the Company is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative anti-tumour therapies. As of the latest practicable date, its pipeline comprises four drug candidates: TSN1611, the core candidate in Phase 2 clinical trials; an additional clinical-stage candidate TSN222; and two preclinical candidates TSNA1789 and TSNA3339.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Tyligand: Re-Files for HKEX Listing for the Second Time; Core Product TSN1611 (KRAS G12D Inhibitor) in Phase 2 Clinical Trials
- KTZ passes HKEX listing hearing: CICC sole sponsor, 99.7% freight share
- ALPHAMAB-B (09966.HK): Wu Jiajun appointed CFO
- JINYAN KAOLIN (02693.HK): NEEQ delisting of domestic shares
- TRANSSION (02636.HK): over-allotment option partly exercised
